Free beta access. 5 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Panviral can’t solve – profit motives, drugs & testing

Jennifer Kahn 4-21-2020 UC Berkeley Graduate School of Journalism “How Scientists Could Stop the Next Pandemic Before It Starts” New York Times Magazine https://www.nytimes.com/2020/04/21/magazine/pandemic-vaccine.html (ermo/sms, Acc:6-22-2022)

But for years, Racaniello notes, the real obstacle to making panviral drugs or vaccines has been that no one was willing to pay for their development. For pharmaceutical companies, he points out, panviral vaccines are simply a terrible business proposition: Companies have to spend hundreds of millions of dollars to develop a shot that people will get once a year at most — and not at all in years when no particular disease is ascendant.

Panviral drug treatments are unprofitable for similar reasons. For one, the course of treatment is short, usually just a few weeks; for chronic diseases (diabetes, high blood pressure), patients take regimens of pills daily, often for years. (One person noted that Gilead’s stock price actually dropped after the company produced a revolutionary hepatitis C drug. Because the treatment completely cured patients, the market for it started to shrink, undermining the company’s bottom line.)

The other problem is that there’s currently no way to quickly test for most viruses, which is essential if a doctor wants to establish a diagnosis and prescribe the right drug. As a result, Racaniello says, it’s “a chicken-and-egg situation: No one is developing drugs for these viruses because there’s no way to test for them. And no one is developing tests, because there aren’t any drugs to prescribe.”

Sign in to recut, update, or save this card.